NNE PharmaplanNNe Pharmaplan is the world’s leading consulting and engineering company in the complex field of pharma and biotech.
NNE Pharmaplan covers all segments from biopharmaceuticals and vaccines to medical devices and helps our customers develop, establish and improve their product manufacturing. We combine engagement in global health issues with a holistic approach focusing on our customers’ need for total solutions.
The company employs 1,700 people at more than 30 locations around the world.
The CEO of NNE Pharmaplan, the world’s leading engineering and consultancy focused in the fields of pharma and biotech, unveils the company’s current opportunities and strategy as it spreads its…
One of NNE Pharmaplan’s latest exciting news is that last year you established offices to accommodate your existing customers in Belgium. What were the strategic motivations for establishing a presence…
Speaking after the recent completion of a three-year strategic transformation plan, ALK President and CEO Carsten Hellmann outlines the progress made by the Danish allergy giant under his stewardship, including…
The BioInnovation Institute (BII) is an initiative from the Novo Nordisk Foundation which aims to support entrepreneurial researchers and early-stage life science start-ups with up to DKK 18 million in…
Lisbeth Nielsen of the Danish Health Data Authority outlines the organisation’s purpose and mission, how it contributed to Denmark’s robust COVID-19 response, and the challenges of making Denmark’s comprehensive patient…
Alphalyse is a Danish contract research organization (CRO) specialising in protein chemistry, mass spectrometry, and bioinformatics. The firm’s co-founder & COO Ejvind Mørtz outlines its journey since its foundation in…
Kasper Bødker Mejlvang oversees Novo Nordisk’s operations in its historic home market of Denmark, as well as Iceland. Here, Bødker Mejlvang explains his strategy for steering the Danish affiliate through…
Newly appointed Director of Invest in Denmark Anne Hougaard Jensen outlines her initial priority list, how the agency is dialling in on the areas in which Denmark has a particular…
Zealand Pharma’s Emmanuel Dulac, fresh from a first US FDA approval for the company’s rescue pen for severe hypoglycaemia in people with diabetes aged 6 years and older, outlines the…
Dr Tina Hahn explains how AXON positions itself as a strategic partner for its Danish clients in their scientific communication work, highlights how the COVID-19 pandemic has foregrounded the importance…
Erik Jylling of the Danish Regions, the organisation charged with healthcare management for each of Denmark’s five regions, outlines the advantages and challenges which persist within Danish healthcare and sounds…
Data has been collected within Danish healthcare for more than 40 years, extending beyond the national patient registry to include a broad range of data points, from IVF to the…
Copenhagen Capacity is Greater Copenhagen’s official organization for investment, promotion, and business development. Its CEO/managing director, Asbjørn Overgaard, outlines the fundamentals attracting life sciences firms to the region, stakeholders’ key…
Danish pharma industry veteran Peter Drøidal highlights how he steered the Danish Novartis affiliate through the COVID-19 pandemic period, the strategy in place to navigate an increasingly challenging market access…
See our Cookie Privacy Policy Here
